TWI754613B - 雜環化合物及其用於預防或治療細菌感染之用途 - Google Patents
雜環化合物及其用於預防或治療細菌感染之用途 Download PDFInfo
- Publication number
- TWI754613B TWI754613B TW105114242A TW105114242A TWI754613B TW I754613 B TWI754613 B TW I754613B TW 105114242 A TW105114242 A TW 105114242A TW 105114242 A TW105114242 A TW 105114242A TW I754613 B TWI754613 B TW I754613B
- Authority
- TW
- Taiwan
- Prior art keywords
- mmol
- oct
- diazabicyclo
- oxy
- alkyl
- Prior art date
Links
- 0 *C(CN(C1)C2=O)=C(*)C1N2O* Chemical compound *C(CN(C1)C2=O)=C(*)C1N2O* 0.000 description 45
- BOXDNKOICZGEDY-UHFFFAOYSA-N CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C Chemical compound CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C BOXDNKOICZGEDY-UHFFFAOYSA-N 0.000 description 4
- KEBPSMMFAMCJCU-UHFFFAOYSA-N CC(C(C1)N2OCC=C)=CCN1C2=O Chemical compound CC(C(C1)N2OCC=C)=CCN1C2=O KEBPSMMFAMCJCU-UHFFFAOYSA-N 0.000 description 2
- GYCPLYCTMDTEPU-UHFFFAOYSA-N Brc1cncnc1 Chemical compound Brc1cncnc1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- WDVMUEQOMCJSTO-XNJYKOPJSA-N C/C=C/P(c1ccccc1)c1ccccc1 Chemical compound C/C=C/P(c1ccccc1)c1ccccc1 WDVMUEQOMCJSTO-XNJYKOPJSA-N 0.000 description 1
- YCUWZRTWPPTYSN-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2I)C1=O Chemical compound C=CCON(C(CN1C2)C=C2I)C1=O YCUWZRTWPPTYSN-UHFFFAOYSA-N 0.000 description 1
- YDVUJBJNECZZCI-UHFFFAOYSA-N C=CCON(C1C(c2cncnc2)=CCN2C1)C2=O Chemical compound C=CCON(C1C(c2cncnc2)=CCN2C1)C2=O YDVUJBJNECZZCI-UHFFFAOYSA-N 0.000 description 1
- QOVVTJCYCPGDOC-UHFFFAOYSA-N C=CCON(C1C(c2ncc[o]2)=CCN2C1)C2=O Chemical compound C=CCON(C1C(c2ncc[o]2)=CCN2C1)C2=O QOVVTJCYCPGDOC-UHFFFAOYSA-N 0.000 description 1
- GMQJPRYCRZDRMJ-UHFFFAOYSA-N CC(C)(C(C)(C)OBB1OC(C)(C)C(C)(C)O1)O Chemical compound CC(C)(C(C)(C)OBB1OC(C)(C)C(C)(C)O1)O GMQJPRYCRZDRMJ-UHFFFAOYSA-N 0.000 description 1
- URVFHZFUXBLTMP-UHFFFAOYSA-N CC(C)(C)OC(NCc1cnc(C(CN(C2)C3=O)=CC2N3O)[s]1)=O Chemical compound CC(C)(C)OC(NCc1cnc(C(CN(C2)C3=O)=CC2N3O)[s]1)=O URVFHZFUXBLTMP-UHFFFAOYSA-N 0.000 description 1
- IVXPCJLPLVOLJN-UHFFFAOYSA-N CCC(CN(C1=O)SC=N)N1OCC=C Chemical compound CCC(CN(C1=O)SC=N)N1OCC=C IVXPCJLPLVOLJN-UHFFFAOYSA-N 0.000 description 1
- DHSPCBLEKLPJIK-UHFFFAOYSA-N CN(C=NC(C(C(C1)N2OCC=C)=C=CN1C2=O)=C1)C1=O Chemical compound CN(C=NC(C(C(C1)N2OCC=C)=C=CN1C2=O)=C1)C1=O DHSPCBLEKLPJIK-UHFFFAOYSA-N 0.000 description 1
- CURWHWKIJDGQOB-UHFFFAOYSA-N COc(nc1)ncc1C(C(C1)N2OCC=C)=CCN1C2=O Chemical compound COc(nc1)ncc1C(C(C1)N2OCC=C)=CCN1C2=O CURWHWKIJDGQOB-UHFFFAOYSA-N 0.000 description 1
- YLUVXTBLSQNNSB-UHFFFAOYSA-N C[Sn](C)(C)C(CN(C1)C2=O)=CC1N2OCC=C Chemical compound C[Sn](C)(C)C(CN(C1)C2=O)=CC1N2OCC=C YLUVXTBLSQNNSB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305701.3 | 2015-05-07 | ||
| EP15305701.3A EP3091018A1 (en) | 2015-05-07 | 2015-05-07 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP16305144 | 2016-02-08 | ||
| EP16305144.4 | 2016-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201643165A TW201643165A (zh) | 2016-12-16 |
| TWI754613B true TWI754613B (zh) | 2022-02-11 |
Family
ID=56083989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105114242A TWI754613B (zh) | 2015-05-07 | 2016-05-06 | 雜環化合物及其用於預防或治療細菌感染之用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183943B2 (enExample) |
| EP (1) | EP3292125B1 (enExample) |
| JP (1) | JP6767392B2 (enExample) |
| KR (1) | KR102713561B1 (enExample) |
| CN (1) | CN107580595B (enExample) |
| AU (1) | AU2016257338B2 (enExample) |
| BR (1) | BR112017023359A2 (enExample) |
| CA (1) | CA2983674A1 (enExample) |
| CL (1) | CL2017002803A1 (enExample) |
| MX (1) | MX2017014080A (enExample) |
| RU (1) | RU2741496C2 (enExample) |
| TW (1) | TWI754613B (enExample) |
| WO (1) | WO2016177862A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170014135A1 (en) | 2015-07-14 | 2017-01-19 | Keith Edward Martin | Surgical tool |
| EP3300736B1 (en) * | 2016-09-30 | 2021-05-05 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP4272831A3 (en) | 2018-08-09 | 2024-02-21 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP5038509B2 (ja) * | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| CN103649088B (zh) * | 2011-08-30 | 2016-05-11 | 沃克哈特有限公司 | 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途 |
| TW201343645A (zh) * | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| BR112014030266B1 (pt) | 2012-06-04 | 2019-06-11 | Elkimia | Compostos imino como agentes de proteção contra radiações ultravioletas |
| US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2015059643A1 (en) * | 2013-10-22 | 2015-04-30 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| CA2980085A1 (en) * | 2015-03-31 | 2016-10-06 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
-
2016
- 2016-05-06 CN CN201680026527.9A patent/CN107580595B/zh active Active
- 2016-05-06 KR KR1020177031802A patent/KR102713561B1/ko active Active
- 2016-05-06 TW TW105114242A patent/TWI754613B/zh not_active IP Right Cessation
- 2016-05-06 RU RU2017135321A patent/RU2741496C2/ru active
- 2016-05-06 BR BR112017023359A patent/BR112017023359A2/pt not_active Application Discontinuation
- 2016-05-06 JP JP2017558028A patent/JP6767392B2/ja active Active
- 2016-05-06 US US15/571,964 patent/US10183943B2/en active Active
- 2016-05-06 MX MX2017014080A patent/MX2017014080A/es unknown
- 2016-05-06 EP EP16725377.2A patent/EP3292125B1/en active Active
- 2016-05-06 WO PCT/EP2016/060142 patent/WO2016177862A1/en not_active Ceased
- 2016-05-06 CA CA2983674A patent/CA2983674A1/en active Pending
- 2016-05-06 AU AU2016257338A patent/AU2016257338B2/en not_active Ceased
-
2017
- 2017-11-06 CL CL2017002803A patent/CL2017002803A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017135321A (ru) | 2019-04-10 |
| JP6767392B2 (ja) | 2020-10-14 |
| NZ736152A (en) | 2024-09-27 |
| CN107580595B (zh) | 2020-09-18 |
| CL2017002803A1 (es) | 2018-05-11 |
| AU2016257338B2 (en) | 2020-03-05 |
| CA2983674A1 (en) | 2016-11-10 |
| KR20180002650A (ko) | 2018-01-08 |
| AU2016257338A1 (en) | 2017-10-26 |
| CN107580595A (zh) | 2018-01-12 |
| TW201643165A (zh) | 2016-12-16 |
| MX2017014080A (es) | 2018-07-06 |
| WO2016177862A1 (en) | 2016-11-10 |
| RU2017135321A3 (enExample) | 2019-08-13 |
| US10183943B2 (en) | 2019-01-22 |
| US20180093985A1 (en) | 2018-04-05 |
| BR112017023359A2 (pt) | 2018-07-17 |
| JP2018515504A (ja) | 2018-06-14 |
| KR102713561B1 (ko) | 2024-10-08 |
| EP3292125A1 (en) | 2018-03-14 |
| RU2741496C2 (ru) | 2021-01-26 |
| EP3292125B1 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7281527B2 (ja) | ベータラクタマーゼ阻害剤化合物 | |
| CN107580595B (zh) | 杂环化合物及它们在预防或治疗细菌感染中的应用 | |
| CN109906226B (zh) | 杂环化合物及它们在预防或治疗细菌感染中的应用 | |
| TW201609725A (zh) | 作為抗癌劑之新穎三環化合物 | |
| TW201639854A (zh) | 雜環化合物及其用於預防或治療細菌感染的用途 | |
| EP3277686B1 (en) | Novel heterocyclic compounds and their use in preventing or treating bacterial infections | |
| CN107438610A (zh) | 杂环化合物及它们在预防或治疗细菌感染中的应用 | |
| JP7589139B2 (ja) | 複素環式化合物及び細菌感染の予防又は治療へのそれらの使用 | |
| EP3091018A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| HK40002917B (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| HK40002917A (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| EA044428B1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| HK1241877A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |